Aaron Allen
Director, Global Quality, Moderna Therapeutics
Aaron Allen is an experienced Manufacturing Sciences and Technology professional with more than 25 years of process engineering, manufacturing and MS&T experience. Mr. Allen has transferred and executed process validation for multiple vaccines within Novartis and Moderna. He has recently transitioned to a new role as Global Quality External Engagement with Moderna.
Mr. Allen’s previous experience includes positions with Diosynth, Biogen, Jacobs Engineering and Novartis Vaccines. Mr. Allen holds a bachelor’s degree in Chemical Engineering from the University of California at Santa Barbara.
Mr. Allen’s previous experience includes positions with Diosynth, Biogen, Jacobs Engineering and Novartis Vaccines. Mr. Allen holds a bachelor’s degree in Chemical Engineering from the University of California at Santa Barbara.
Appearances
DateJune 28, 2022The outbreak of COVID-19 brought the mRNA technology to light. From a silent long-term technology that needed to prove its potential, well behind other technologies like C&G therapies, to the focus of everyone's attention…Speakers
Vice President, Global Quality Systems and Compliance, ModernaDavid Estapé, PhDTechnology Manager Biotechnology, CRB Group GmbHDirector, Global Quality, Moderna TherapeuticsPresident, BioNTechGlobal Quality and External Collaboration Manager At Roche, F. Hoffmann La Roche Ltd
DateMarch 6, 2023In the end, it all comes down to manufacturing the drugs on a commercial scale. Many challenges have to be overcome. This year’s aseptic conference has dedicated two sessions to manufacturing case studies…Session Leader
Senior Product Manager, Syntegon Technology GmbHSpeakers
Director, Global Quality, Moderna TherapeuticsChief Business Officer, Oncomed Manufacturing A.s.Kara Vogt, PhDProcess Engineer, Technical Services, INCOG BioPharma ServicesPrincipal Technical Operations Engineer, INCOG BioPharma Services
DateJune 27, 2023The rapid introduction of a pandemic vaccine created a challenge to the classical sequential approach to process characterization, transfer, and validation at production scale. The lessons learned from this unprecedented opportunity allows for rapid introduction of related variants…Speaker
Director, Global Quality, Moderna Therapeutics
DateOctober 17, 2023To wrap up the ATMP and Advanced Technologies Track, what could be more fitting than a discussion on the latest advancements in ATMPs? Since the first CAR-T therapy was approved in 2017, the industry, regulators, and even the general public's understanding of ATMPs has grown significantly…Session Leader
QA Specialist, Bachem AGSpeakers
Principle Process Architect/SME, Jacobs EngineeringProcess Subject Matter Expert, Jacobs Engineering Group IncAssociate Director Process Engineering, Regenerative Medicine, United TherapeuticsSenior Process Engineer, Jacobs Engineering Group IncDirector of Advanced Therapies and Biologics, PM GroupDirector, Global Quality, Moderna TherapeuticsDirector, Regulatory Compliance, Jacobs , Life Sciences
DateOctober 16, 2023It's remarkable how rapidly the field of ATMP development is advancing, with more and more organizations entering this space. In this session, we'll take a closer look at how a conventional biologics manufacturing facility was transformed into a modern, multi-modal facility for ATMP products…Session Leader
Technical Director, No Deviation Pte LtdSpeakers
Head of Real Estate, Facilities and Capital Programs, Spark Therapeutics, Inc.Vice President Site Engineering, BayerDirector Platform Engineering, BayerVice President of Pharmaceutical Engineering, Sarepta TherapeuticsRincipal and Founder, Baseline Controls, IncVP of Strategy, Project FarmaSenior Director of Architecture/ Process Architecture SME, PM GroupHead of Project Delivery US (Exec Director), Genentech IncDirector, Global Quality, Moderna Therapeutics
